Success Metrics

Clinical Success Rate
88.9%

Based on 24 completed trials

Completion Rate
89%(24/27)
Active Trials
1(3%)
Results Posted
33%(8 trials)
Terminated
3(8%)

Phase Distribution

Ph not_applicable
2
6%
Ph early_phase_1
2
6%
Ph phase_1
12
33%
Ph phase_2
4
11%

Phase Distribution

14

Early Stage

4

Mid Stage

0

Late Stage

Phase Distribution20 total trials
Early Phase 1First-in-human
2(10.0%)
Phase 1Safety & dosage
12(60.0%)
Phase 2Efficacy & side effects
4(20.0%)
N/ANon-phased studies
2(10.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

80.0%

24 of 30 finished

Non-Completion Rate

20.0%

6 ended early

Currently Active

1

trials recruiting

Total Trials

36

all time

Status Distribution
Active(3)
Completed(24)
Terminated(6)
Other(3)

Detailed Status

Completed24
Withdrawn3
unknown3
Terminated3
Not yet recruiting2
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
36
Active
1
Success Rate
88.9%
Most Advanced
Phase 2

Trials by Phase

Early Phase 12 (10.0%)
Phase 112 (60.0%)
Phase 24 (20.0%)
N/A2 (10.0%)

Trials by Status

withdrawn38%
not_yet_recruiting26%
recruiting13%
unknown38%
terminated38%
completed2467%

Recent Activity

Clinical Trials (36)

Showing 20 of 36 trialsScroll for more
NCT01795313Phase 1

Immunotherapy for Recurrent Ependymomas in Children Using Tumor Antigen Peptides With Imiquimod

Terminated
NCT06991985

Analysis of Factors Associated With The Occurrence of Amniotic Fluid Entry in Patients Undergoing Caesarean Section

Not Yet Recruiting
NCT06460142

Assessing Biomarker in Giant Cell Arteritis and Polymyalgia Rheumatic

Recruiting
NCT06469047

Relationship Between Serum N/OFQ and Acute Myeloid Cell Leukemia

Not Yet Recruiting
NCT01407770

Genetic Susceptibility to Radiation-Induced Skin Reactions in Racial/Ethnic Groups of Patients With Breast Cancer

Completed
NCT01385059Phase 2

Axitinib Before Surgery in Treating Patients With High-Risk Prostate Cancer

Completed
NCT05344794

Relationship Between Serum N/OFQ and Brain-heart Syndrome

Unknown
NCT01165645Not Applicable

Lopinavir and Ritonavir in Improving Immune Response to Vaccines in Patients With Complete Remission Following A Bone Marrow Transplant for Hodgkin Lymphoma

Withdrawn
NCT01582009Phase 1

Panobinostat and Everolimus in Treating Patients With Metastatic or Unresectable Renal Cell Cancer That Does Not Respond to Treatment With Sunitinib Malate or Sorafenib Tosylate

Terminated
NCT01673217Phase 1

Decitabine, Vaccine Therapy, and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer

Completed
NCT01497392Phase 1

Dovitinib Lactate, Gemcitabine Hydrochloride, and Capecitabine in Treating Patients With Advanced or Metastatic Solid Tumors, Pancreatic Cancer and Biliary Cancers

Completed
NCT01192815Phase 2

Erlotinib Hydrochloride and Radiation Therapy in Stage III-IV Squamous Cell Cancer of the Head and Neck

Terminated
NCT00985868Phase 1

AT9283 in Children and Adolescents With Relapsed and Refractory Solid Tumors

Completed
NCT01562288

Studying Blood and DNA Samples From Patients With Breast Cancer Treated With Chemotherapy With or Without Trastuzumab

Completed
NCT00357448Phase 1

Denileukin Diftitox Used in Treating Patients With Advanced Refractory Ovarian Cancer, Primary Peritoneal Carcinoma, or Epithelial Fallopian Tube Cancer

Completed
NCT00425672Phase 1

ONTAK® in Treating Patients With Advanced Breast Cancer That Did Not Respond to Previous Treatment

Completed
NCT01385280Not Applicable

Pilot Study Estradiol Followed by Exemestane Hormone Receptor + Metastatic Breast Cancer

Completed
NCT01270880Phase 2

Hsp90 Inhibitor STA-9090 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy

Completed
NCT01273766Phase 2

Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies

Completed
NCT00986609Early Phase 1

MUC1 Vaccine for Triple-negative Breast Cancer

Completed

Drug Details

Intervention Type
OTHER
Total Trials
36